Nebivolol +pharma (Nebivolol Hydrochloride)

Nebivolol selectively blocks β1‑adrenergic receptors in the heart, decreasing heart rate and contractility. It also stimulates nitric‑oxide release from the endothelium, causing vasodilation. The combined effect reduces cardiac output and systemic vascular resistance, leading to lower blood pressure.

The exact dose of nebivolol is determined by the prescribing clinician based on the patient’s medical condition, age, renal function, and response to therapy. Dosage may be started low and titrated upward, but the specific regimen should always follow the prescriber’s instructions.

Nebivolol’s safety in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nebivolol is a highly selective β1‑blocker with additional nitric‑oxide‑mediated vasodilatory activity, which may result in fewer metabolic side effects compared with non‑selective beta blockers. Its dual mechanism can provide better blood‑pressure control while preserving endothelial function, distinguishing it from older agents such as atenolol or metoprolol.

Nebivolol +pharma tablets should be stored at ambient temperature, below 25 °C. Keep them in the original packaging to protect from moisture and light, and store out of reach of children.

Nebivolol +pharma is taken orally, usually once daily with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include severe bradycardia, marked hypotension, heart block, and bronchospasm in patients with reactive airway disease. Patients should be monitored for signs of these conditions, especially when initiating therapy or adjusting the dose.

Nebivolol is contraindicated in patients with known hypersensitivity to the drug, severe bradycardia, second‑ or third‑degree atrioventricular block, cardiogenic shock, or uncontrolled asthma. It should also be used with caution in individuals with severe liver impairment or decompensated heart failure.